GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over
The National Health Care Institute has completed its assessment whether trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over can be included in the Medication Reimbursement System (GVS). The National Health Care Institutes advice is to include trifarotene (Aklief®) on List 1A of the GVS in cluster 0D10ADADC V.
Registered indication
Trifarotene (Aklief®) is a retinoid, indicated for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over when a large amount of comedones, papules and pustules are present.
Interchangeability
Based on the criteria for interchangeability, it can be concluded that trifarotene (Aklief®) is interchangeable with the other medicinal products in the GVS cluster 0D10ADADC V, which includes: tretinoin, adapalene and adapalene/benzoyl peroxide.
The National Health Care Institute's advice
The National Health Care Institute advices the Minister of Medical Care to include trifarotene (Aklief®) on List 1A in cluster 0D10ADADC V of the GVS. 1 gram can be used as a standard dosage.